

NZX Announcement

4 May 2020

TruScreen Limited (NZX:TRU) (TruScreen or the “Company”) has today released three videos introducing Mrs Victoria Potarina, Chief Executive Officer (CEO), outlining the Company’s strategy, and the CEO’s thoughts on building a global medical device company.

Video	Website Link	Website Text	Youtube Link
Introduction Video	https://truscreen.com/news/video-introduction-to-truscreens-ceo-victoria-potarina/	Get to know TruScreen’s new CEO, Mrs Victoria Potarina, who joined the company in March 2020. Mrs Potarina brings more than twenty years’ commercial experience, previously working at Johnson & Johnson (J&J) in both the UK and across Europe. In addition, she has held positions at multiple multinational companies in the FMCG, over-the-counter, medical devices and healthcare sectors.	https://www.youtube.com/watch?v=5K86ri95gOc
Growth Strategy	https://truscreen.com/news/video-truscreen-limiteds-growth-strategy-for-2020-and-beyond/	TruScreen’s CEO, Mrs. Victoria Potarina, discusses with Ms Marisa Zammit TruScreen’s growth strategy and the pillars that form the foundation of the strategy.	https://www.youtube.com/watch?v=CipVNkbWl1I
Building a Global Medical Device Company	https://truscreen.com/news/video-building-a-global-medical-device-company/	TruScreen CEO, Mrs Victoria Potarina, discusses what it takes to build a global medical device company. Mrs. Potarina speaks to the vital areas that TruScreen will be investing in and the company’s priorities as it moves into the next stage of commercialisation.	https://www.youtube.com/watch?v=xDXHL7ltLi8&t=107s

This announcement has been approved by the Board.

- ENDS -

For more information, visit www.truscreen.com or contact:

TruScreen

Victoria Potarina

Chief Executive Officer

victoriapotarina@truscreen.com

Guy Robertson

Chief Financial Officer

guyrobertson@truscreen.com

About TruScreen:

TruScreen is a Cervical Cancer Screening Device which offers the latest technology in cervical screening, providing real-time, accurate detection of pre-cancerous and cancerous cervical cells to help improve the health and well-being of women around the world. TruScreen's real-time cervical cancer technology utilises a digital wand which is placed on the surface of the cervix to measure electrical and optical signals from the surrounding tissues. A sophisticated proprietary algorithm framework is utilised to detect pre-cancerous change, or cervical intra-epithelial neoplasia (CIN), by optical and electrical measurement of cervical tissue.



TruScreen offers an alternative approach to cervical screening, resolving many of the ongoing issues with Pap tests, including failed samples, poor patient follow-up, patient discomfort and the need for supporting laboratory infrastructures. As such, TruScreen's target market is low- and middle-income countries where no large-scale cervical cancer screening programs and infrastructure are in place, such as China, Mexico, Africa, Russia and India. TruScreen's cervical cancer screening device is CE-marked and certified for use throughout Europe and CFDA-approved for sale in China. The global market potential for TruScreen is significant.

For more information, visit our website at www.truscreen.com

Watch our video on TruScreen: <http://truscreen.com/truscreen-the-company/truscreen-ultra-video/>